Friday 22 March 2019

Reuters Health Report: UPS eyes in-home health services with U.S. vaccine project

Reuters.com Newsletter

UPS eyes in-home health services with U.S. vaccine project

LOUISVILLE, Ky. - United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare.

China urges subsidies to help disease-hit pig farms restock

China has urged rural governments to offer temporary subsidies to pig breeding farms and large-scale producers to help stabilize hog production, as fears grow about the impact of a severe disease outbreak on pork supplies.

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

China birth rates fall in several regions in 2018: China Daily

China's birth rate in several regions, including the capital Beijing, fell again in 2018, the official China Daily said on Friday, despite government efforts to encourage couples to have more children.

FDA says cybersecurity vulnerabilities found in some Medtronic devices

The U.S. Food and Drug Administration (FDA) on Thursday said cybersecurity vulnerabilities were identified in Medtronic Plc's implantable cardiac devices, clinic programmers, and home monitors.

J&J to record $700 million charge related to abandoned drug program

Johnson & Johnson on Thursday said it will record a nearly $700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.

Long-term hormone use after menopause tied to Alzheimer's risk

(Reuters Health) - Women who take hormone replacement therapy (HRT) to ease menopause symptoms like hot flashes and night sweats may be slightly more likely to develop Alzheimer's disease, a large Finnish study suggests.

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.

Phone app may help conquer fear of heights

(Reuters Health) - People who are terrified of heights may be able to conquer their phobia using a virtual reality app and an inexpensive set of cardboard VR googles, a Dutch study suggests.

Mississippi governor signs 'heartbeat' abortion ban

Mississippi's Republican governor signed one of America's strictest abortion bills on Thursday banning women from obtaining an abortion once a fetal heartbeat is detected, which can often occur before a woman even realizes she is pregnant.

Heart risk factors may predict lung damage in 9-11 responders

(Reuters Health) - For firefighters who worked at "Ground Zero" around September 11, 2001, a group of heart-disease risk factors also predicted who was likely to develop World Trade Center-related lung injury years later, researchers say.

Related Videos

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS